These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17004081)

  • 21. Costs of illness in a Russian cohort of patients with Parkinson's disease.
    Winter Y; von Campenhausen S; Popov G; Reese JP; Klotsche J; Bötzel K; Gusev E; Oertel WH; Dodel R; Guekht A
    Pharmacoeconomics; 2009; 27(7):571-84. PubMed ID: 19663528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis].
    Westhoff G; Listing J; Zink A
    Z Rheumatol; 2004 Oct; 63(5):414-24. PubMed ID: 15517302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cost of multiple sclerosis in France].
    Fromont A; Lehanneur MN; Rollot F; Weill A; Clerc L; Bonithon Kopp C; Binquet C; Moreau T
    Rev Neurol (Paris); 2014; 170(6-7):432-9. PubMed ID: 24856285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany.
    Hamer HM; Spottke A; Aletsee C; Knake S; Reis J; Strzelczyk A; Oertel WH; Rosenow F; Dodel R
    Epilepsia; 2006 Dec; 47(12):2165-72. PubMed ID: 17201718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Direct and indirect costs of fractures due to osteoporosis in Austria].
    Dimai HP; Redlich K; Schneider H; Siebert U; Viernstein H; Mahlich J
    Gesundheitswesen; 2012 Oct; 74(10):e90-8. PubMed ID: 22422076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study].
    Liebl A; Neiss A; Spannheimer A; Reitberger U; Wagner T; Görtz A
    Dtsch Med Wochenschr; 2001 May; 126(20):585-9. PubMed ID: 11402924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic aspects of Parkinson disease treatment].
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():215-6. PubMed ID: 10916053
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease.
    Valldeoriola F; Morsi O; Tolosa E; Rumià J; Martí MJ; Martínez-Martín P
    Mov Disord; 2007 Nov; 22(15):2183-91. PubMed ID: 17724747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.
    Dodel RC; Höffken H; Möller JC; Bornschein B; Klockgether T; Behr T; Oertel WH; Siebert U
    Mov Disord; 2003 Oct; 18 Suppl 7():S52-62. PubMed ID: 14531047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].
    Baltin CT; Smaczny C; Wagner TO
    Med Klin (Munich); 2010 Dec; 105(12):887-900. PubMed ID: 21240588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy].
    Dodel RC; Pepperl S; Köhne-Volland R; Szucs T; Werhahn KJ; Noachtar S; Oertel WH
    Med Klin (Munich); 1996 Jul; 91(7):479-85. PubMed ID: 8756119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost measurement based on a cost diary in patients with inflammatory bowel disease].
    Rösch M; Leidl R; Tirpitz Cv; Reinshagen M; Adler G; König HH
    Z Gastroenterol; 2002 Apr; 40(4):217-28. PubMed ID: 11961730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Costs associated with multiresistant bacteria in neurorehabilitation].
    Roukens R; Lauster F; Bara M; Eifert B; Willemsen D; Randall T; Herzog J; Wendt C; Schmidt-Wilcke T; Knecht S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Oct; 60(10):1075-1082. PubMed ID: 28812106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAPECO: Cost evaluation of community acquired pneumonia managed in primary care.
    Personne V; Chevalier J; Buffel du Vaure C; Partouche H; Gilberg S; de Pouvourville G
    Vaccine; 2016 Apr; 34(19):2275-80. PubMed ID: 26979138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease.
    Bach JP; Riedel O; Klotsche J; Spottke A; Dodel R; Wittchen HU
    J Neurol Sci; 2012 Mar; 314(1-2):41-7. PubMed ID: 22133477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.